

Nicolas Roberto Robles

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9567584/publications.pdf>

Version: 2024-02-01

122
papers

978
citations

623734

14
h-index

610901

24
g-index

146
all docs

146
docs citations

146
times ranked

1311
citing authors

#	ARTICLE	IF	CITATIONS
1	Perfil clínico de los pacientes tratados con evolocumab en unidades hospitalarias de nefrología en España (RETOSS-NEFRO). <i>Nefrologia</i> , 2022, 42, 301-310.	0.4	1
2	Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2022, 29, 137-144.	2.2	1
3	Tag-SNPs in Phospholipase-Related Genes Modify the Susceptibility to Nephrosclerosis and its Associated Cardiovascular Risk. <i>Frontiers in Pharmacology</i> , 2022, 13, 817020.	3.5	3
4	Historical Archive of Blood Pressure and Evolution of Hypertension. <i>Journal of Drug Delivery and Therapeutics</i> , 2022, 12, 215-219.	0.5	0
5	Cardiovascular risk assessment after one-year acute ischemic stroke based on uric acid levels and renal dysfunction. A clinical study. <i>International Journal of Neuroscience</i> , 2021, 131, 609-614.	1.6	2
6	The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI) clinical phenotypes and their predictors based on a cohort of 1000 patients. <i>Cardiovascular Research</i> , 2021, 117, 950-959.	3.8	33
7	Efecto de la enfermedad renal crónica sobre la incidencia de episodios cardiovasculares en población española. <i>Medicina Clínica</i> , 2021, 157, 569-574.	0.6	0
8	Hypertension in Kidney Transplant Recipients: Where Are We Today?. <i>Current Hypertension Reports</i> , 2021, 23, 21.	3.5	5
9	Validation of the QMon-20 oscillometric blood pressure monitor for professional office use in the general population according to the ANSI/ESH/ISO 81060-2:2018 protocol. <i>Blood Pressure Monitoring</i> , 2021, 26, 393-395.	0.8	0
10	Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome (CRS). <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2021, 19, 93-97.	1.0	8
11	Maximum doses of renin-angiotensin axis blockers in diabetic nephropathy?. <i>Medicina Clínica (English)</i> Tj ETQq1 10,784314,rgBT /O	0.2	0
12	¿Dosis máximas de bloqueantes del eje renina-angiotensina en nefropatía diabética?. <i>Medicina Clínica</i> , 2021, 157, 20-21.	0.6	1
13	Genetic Variants in PGE2 Receptors Modulate the Risk of Nephrosclerosis and Clinical Outcomes in These Patients. <i>Journal of Personalized Medicine</i> , 2021, 11, 772.	2.5	4
14	Antiretroviral Treatment and Antihypertensive Therapy. <i>Current Pharmaceutical Design</i> , 2021, 27, 4116-4124.	1.9	0
15	Genetics Variants in the Epoxygenase Pathway of Arachidonic Metabolism Are Associated with Eicosanoids Levels and the Risk of Diabetic Nephropathy. <i>Journal of Clinical Medicine</i> , 2021, 10, 3980.	2.4	7
16	Systolic Blood Pressure and Outcomes in Stable Outpatients with Recent Symptomatic Artery Disease: A Population-Based Longitudinal Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 9348.	2.6	6
17	KDIGO guidelines for the management of blood pressure in chronic kidney disease: A sprint to the curve. <i>European Journal of Internal Medicine</i> , 2021, 93, 21-23.	2.2	1
18	Efecto del cambio en el peso tras el trasplante renal en la supervivencia del injerto. <i>Nefrologia</i> , 2021, ,	0.4	0

#	ARTICLE	IF	CITATIONS
19	Alfa-1-microglobulina: valor pronóstico en la enfermedad renal crónica. Medicina Clínica, 2021, 157, 368-370.	0.6	7
20	Alpha-1-microglobulin: Prognostic value in chronic kidney disease. Medicina Clínica (English Edition), 2021, 157, 368-370.	0.2	3
21	Pitavastatin: Similarities and Differences Compared With Other Statins. ACTA Pharmaceutica Scientia, 2021, 59, 655-669.	0.2	0
22	Plasma and urinary concentrations of arachidonic acid-derived eicosanoids are associated with diabetic kidney disease. EXCLI Journal, 2021, 20, 698-708.	0.7	3
23	Study of the effect of chronic kidney disease on the incidence of cardiovascular events in a native Spanish population. Medicina Clínica (English Edition), 2021, , .	0.2	0
24	Recomendaciones de manejo de la afectación renal en el complejo esclerosis tuberosa. Nefrología, 2020, 40, 142-151.	0.4	4
25	PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 43-49.	2.2	4
26	Automated blood pressure measurement in consultation. Medicina Clínica (English Edition), 2020, 154, 59-60.	0.2	0
27	Nuevos aspectos en la vigilancia epidemiológica con relación a las enfermedades virales en hemodiálisis. Nefrología, 2020, 40, 570-571.	0.4	0
28	Proton pump inhibitors and risk for recurrent ischemic events or death in outpatients with symptomatic artery disease. Atherosclerosis, 2020, 292, 84-89.	0.8	6
29	New aspects in epidemiological surveillance in relation to viral diseases in haemodialysis. Nefrología, 2020, 40, 570-571.	0.4	0
30	Recommendations for the management of renal involvement in tuberous sclerosis complex. Nefrología, 2020, 40, 142-151.	0.4	2
31	Risk factors for non-diabetic renal disease in diabetic patients. CKJ: Clinical Kidney Journal, 2020, 13, 380-388.	2.9	14
32	Does established vascular kidney disease exist?. Journal of Clinical Hypertension, 2020, 22, 296-298.	2.0	5
33	Medición automatizada de presión arterial en consulta. Medicina Clínica, 2020, 154, 59-60.	0.6	0
34	SP306A PROSPECTIVE STUDY OF THE EFFECT OF CHRONIC KIDNEY DISEASE ON THE INCIDENCE OF CARDIOVASCULAR EVENTS IN A NATIVE SPANISH POPULATION. Nephrology Dialysis Transplantation, 2019, 34, .	0.7	0
35	Polymorphisms in vasoactive eicosanoid genes of kidney donors affect biopsy scores and clinical outcomes in renal transplantation. PLoS ONE, 2019, 14, e0224129.	2.5	3
36	Prognostic Role of Hyponatremia in Heart Failure Patients Depending on Renal Disease: Clinical Evidence. Cardiology, 2019, 144, 1-8.	1.4	3

#	ARTICLE	IF	CITATIONS
37	J-shaped curve for cardiovascular mortality: systolic or diastolic blood pressure?. Journal of Nephrology, 2019, 32, 347-353.	2.0	5
38	Association between serum uric acid and carotid disease in patients with atherosclerotic acute ischemic stroke. Vascular, 2019, 27, 19-26.	0.9	13
39	Serum uric acid levels and outcome during admission in acute ischaemic stroke, depending on renal function. International Journal of Neuroscience, 2018, 128, 906-912.	1.6	9
40	A comparison of cystatin C concentrations between patients with chronic interstitial nephritis and glomerular diseases. Journal of Clinical Laboratory Analysis, 2018, 32, .	2.1	1
41	Anemia as very late onset cytomegalovirus disease after kidney transplantation. Transplant Infectious Disease, 2018, 20, e12797.	1.7	2
42	SP416DIABETIC PATIENTS WITH DIABETIC NEPHROPATHY HAVE WORSE RENAL PROGNOSIS. STUDY BIODIAB-GLOSEN-GEENDIAB. Nephrology Dialysis Transplantation, 2018, 33, i487-i487.	0.7	0
43	Lack of Correlation of Carotid Intima-Media Index and Peripheral Artery Disease. High Blood Pressure and Cardiovascular Prevention, 2018, 25, 379-383.	2.2	1
44	PAIT-survey Prevalence of albuminuria in patients with diabetes and hypertension in Turkey. Primary Care Diabetes, 2018, 12, 558-564.	1.8	6
45	SP425RENAL BIOPSY IN DIABETIC PATIENTS: PRELIMINARY RESULTS OF THE SPANISH MULTICENTER STUDY BIODIAB-GLOSEN-GEENDIAB. Nephrology Dialysis Transplantation, 2018, 33, i491-i491.	0.7	0
46	Iron deficiency in chronic kidney disease patients with diabetes mellitus. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2018, 12, 933-937.	3.6	10
47	Non-proteinuric diabetic nephropathy is the main cause of chronic kidney disease: Results of a general population survey in Spain. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2017, 11, S777-S781.	3.6	14
48	Does a blood pressure J curve exist for patients with chronic kidney disease?. Journal of Clinical Hypertension, 2017, 19, 764-770.	2.0	13
49	Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug. Expert Opinion on Investigational Drugs, 2017, 26, 651-659.	4.1	11
50	Afectación glomerular en paciente con enfermedad falciforme. Nefrología, 2017, 37, 437-439.	0.4	0
51	Glomerular involvement in patient with sickle cell disease. Nefrología, 2017, 37, 437-439.	0.4	0
52	[PP.07.12] HEMATOCRIT UREA AND GENDER (H.U.G.E.) FORMULA AND THE CKD PROGNOSIS CONSORTIUM EQUATION. Journal of Hypertension, 2017, 35, e140.	0.5	0
53	Dihydropyridine calcium channel blockers and renal disease. Hypertension Research, 2017, 40, 21-28.	2.7	16
54	Lercanidipine in the management of hypertension: An update. Journal of Pharmacology and Pharmacotherapeutics, 2017, 8, 155.	0.4	24

#	ARTICLE	IF	CITATIONS
55	Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 128.	2.7	11
56	Erythropoietin, chronic renal failure and cancer. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 539-540.	0.2	0
57	MPO39THE EFFECT OF EVEROLIMUS IN PATIENTS WITH RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, i355-i356.	0.7	0
58	Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. <i>Current Medical Research and Opinion</i> , 2016, 32, 29-34.	1.9	10
59	The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease. <i>Clinical Drug Investigation</i> , 2016, 36, 421-431.	2.2	13
60	Secondary hyperparathyroidism prevalence and profile, between diabetic and non-diabetic patients with stage 3 to 4 chronic kidney disease attended in internal medicine wards. MiPTH study. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2016, 10, S16-S21.	3.6	6
61	Cystatin C as a mortality predictor in a hypertensive population in Extremadura, Spain. <i>Medicina Clínica (English Edition)</i> , 2015, 145, 198-200.	0.2	0
62	PP.32.08. <i>Journal of Hypertension</i> , 2015, 33, e422.	0.5	1
63	Non-Proteinuric Diabetic Nephropathy. <i>Journal of Clinical Medicine</i> , 2015, 4, 1761-1773.	2.4	49
64	SP468DIABETES MELLITUS AND RENAL DISEASE: RESULTS OF A GENERAL POPULATION SURVEY IN SPAIN. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii535-iii535.	0.7	0
65	Prevalencia del hiperparatiroidismo secundario en pacientes con enfermedad renal crónica estadios 3 y 4 atendidos en medicina interna. <i>Endocrinología Y Nutricion: Organo De La Sociedad Espanola De Endocrinología Y Nutricion</i> , 2015, 62, 300-305.	0.8	11
66	The H.U.G.E. formula (hematocrit, urea, sex) for screening chronic kidney disease (CKD) in an age-stratified general population. <i>Journal of Nutrition, Health and Aging</i> , 2015, 19, 688-692.	3.3	10
67	Prevalence of secondary hyperparathyroidism in patients with stage 3 and 4 chronic kidney disease seen in internal medicine. <i>Endocrinología Y Nutrición (English Edition)</i> , 2015, 62, 300-305.	0.5	8
68	Atherosclerotic ischemic renal disease: Clinical challenges. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 163-165.	0.2	0
69	Hypertension in the Elderly. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2015, 12, 136-145.	1.0	30
70	Research update for articles published in EJCI in 2012. <i>European Journal of Clinical Investigation</i> , 2014, 44, 1010-1023.	3.4	1
71	Use of Î±1-microglobulin for diagnosing chronic interstitial nephropathy. <i>Clinical and Experimental Medicine</i> , 2014, 14, 315-320.	3.6	9
72	Erythropoiesis stimulating agents (ESAs) for congestive heart failure: The red and the black. <i>European Journal of Internal Medicine</i> , 2014, 25, 193-196.	2.2	2

#	ARTICLE	IF	CITATIONS
73	Renin-angiotensin System Blocking Drugs. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 14-33.	2.0	53
74	Prevalence of obesity and associated cardiovascular risk: the DARIOS study. BMC Public Health, 2013, 13, 542.	2.9	48
75	Intensive treatment of persistent microalbuminuria: determinants of treatment resistance. Open Medicine (Poland), 2013, 8, 302-309.	1.3	0
76	Características clínicas y mortalidad de la insuficiencia cardiaca. Estudio INCAex. Revista Clínica Española, 2013, 213, 16-24.	0.6	8
77	Increased frequency of microalbuminuria in patients receiving statins. Clinical Lipidology, 2013, 8, 257-262.	0.4	6
78	Prevalence of abnormal urinary albumin excretion in elderly people: a Spanish survey. International Urology and Nephrology, 2013, 45, 553-560.	1.4	12
79	Cross-sectional survey of the prevalence of reduced estimated glomerular filtration rate, albuminuria and cardiovascular risk in a native Spanish population. Journal of Nephrology, 2013, 26, 675-682.	2.0	13
80	The HUGE formula (hematocrit, urea and gender): association with cardiovascular risk. European Review for Medical and Pharmacological Sciences, 2013, 17, 1889-93.	0.7	5
81	Estimated Glomerular Filtration Rate from Serum Cystatin C: Significant Differences among Several Equations Results. Renal Failure, 2012, 34, 871-875.	2.1	4
82	Prevalence of abnormal urinary albumin excretion in a population-based study in Spain: results from the HERMEX Study. European Journal of Clinical Investigation, 2012, 42, 1272-1277.	3.4	12
83	A proposal for improving the KDIGO renal disease risk table. International Urology and Nephrology, 2012, 44, 1431-1433.	1.4	0
84	Hematocrit, urea and gender: The Hematocrit, Urea and Gender formula for prognosing progressive renal failure in diabetic nephropathy. European Journal of Internal Medicine, 2012, 23, 283-286.	2.2	12
85	Blood Pressure in Renal Disease: How to Accomplish the Goal?. Cardiovascular Therapeutics, 2012, 30, 193-198.	2.5	14
86	Persistent microalbuminuria after treatment with renin-angiotensin axis blockers: causes and results of treatment intensification. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2011, 12, 333-339.	1.7	8
87	Glomerular filtration rate estimated from serum cystatin. International Journal of Clinical Practice, 2011, 65, 1108-1109.	1.7	0
88	The value of a formula including haematocrit, blood urea and gender (HUGE) as a screening test for chronic renal insufficiency. Journal of Nutrition, Health and Aging, 2011, 15, 480-484.	3.3	28
89	Symmetrical Ambulatory Arterial Stiffness Index: Relationship with Serum Cystatin C Levels. Renal Failure, 2011, 33, 255-260.	2.1	6
90	Cardiovascular Risk in Uremic Patients: Darkness after AURORA. Renal Failure, 2010, 32, 269-272.	2.1	1

#	ARTICLE	IF	CITATIONS
91	Treatment of Proteinuria with Lercanidipine Associated with Renin-Angiotensin Axis-Blocking Drugs. Renal Failure, 2010, 32, 192-197.	2.1	22
92	Edema agudo de pulmÃ³n no cardiogÃ©nico por hidroclorotiazida. Hipertension Y Riesgo Vascular, 2010, 27, 128-129.	0.6	1
93	Symmetrical ambulatory arterial stiffness index: Relationship with microalbuminuria and renal function. European Journal of Internal Medicine, 2010, 21, 118-122.	2.2	10
94	Cystatin c and blood pressure: Results of 24h ambulatory blood pressure monitoring. European Journal of Internal Medicine, 2010, 21, 185-190.	2.2	14
95	Plasma cystatin C for prediction of 1-year cardiac events in Mediterranean patients with non-ST elevation acute coronary syndrome. Atherosclerosis, 2010, 209, 300-305.	0.8	55
96	Hidden chronic renal insufficiency and cardiovascular events in patients with hypertension in a primary care center. Renal Failure, 2010, 32, 757-765.	2.1	5
97	Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for diabetic nephropathy: a retrospective comparison. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2009, 10, 195-200.	1.7	5
98	Dual renin-angiotensin system blockade: In patients with single functioning kidney and proteinuria. European Journal of Internal Medicine, 2009, 20, 186-189.	2.2	2
99	Long-Term Antiproteinuric Effect of Dual Renin-Angiotensin System Blockade. Cardiovascular Therapeutics, 2009, 27, 101-107.	2.5	2
100	Dual renin-angiotensin system blockade: on the target. International Journal of Clinical Practice, 2008, 62, 1134-1136.	1.7	0
101	Effectiveness of eprosartan in diabetic hypertensive patients. European Journal of Internal Medicine, 2008, 19, 27-31.	2.2	6
102	Limitaciones de la automedicaciÃ³n de la presiÃ³n arterial. Hipertension, 2008, 25, 81-82.	0.0	0
103	Calcium Antagonists and Renal Failure Progression. Renal Failure, 2008, 30, 247-255.	2.1	12
104	Fixed-Dose Combination Lercanidipine/Enalapril. Drugs, 2007, 67, 107-108.	10.9	0
105	Do we need glomerular filtration rate calculation?. International Journal of Clinical Practice, 2007, 61, 1611-1613.	1.7	4
106	Untoward effects of chronic dual renin-angiotensin system blockade: influence of previous chronic renal failure. International Journal of Clinical Practice, 2006, 60, 1035-1039.	1.7	8
107	Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients. International Journal of Clinical Practice, 2005, 59, 478-484.	1.7	9
108	Hyperhomocysteinemia in patients with mild chronic renal failure. European Journal of Internal Medicine, 2005, 16, 334-338.	2.2	9

#	ARTICLE	IF	CITATIONS
109	Comparative Effects of Fosinopril and Irbesartan on Hematopoiesis in Essential Hypertensives. Renal Failure, 2004, 26, 399-404.	2.1	24
110	Lercanidipine in chronic renal failure (CRF). American Journal of Hypertension, 2003, 16, A99-A100.	2.0	0
111	Nighttime Blood Pressure Fall in Renal Disease Patients. Renal Failure, 2003, 25, 829-837.	2.1	5
112	Sympathetic Skin Response in Peritoneal Dialysis Patients. ASAIO Journal, 2003, 49, 88-91.	1.6	5
113	ACUTE EFFECT OF HEMODIALYSIS ON SYMPATHETIC SKIN RESPONSE. Renal Failure, 2001, 23, 843-850.	2.1	1
114	ACUTE EFFECT OF HEMODIALYSIS WITH POLYACRYLONITRILE MEMBRANE ON NERVE CONDUCTION VELOCITIES. Renal Failure, 2001, 23, 251-257.	2.1	3
115	N.R. Robles. Medicina Clínica, 2000, 114, 679.	0.6	0
116	Sympathetic Skin Response in Hemodialysis Patients: Correlation with Nerve Conduction Studies and Adequacy of Dialysis. Nephron, 1999, 82, 12-16.	1.8	9
117	1997 Spanish Nephrology Association (Sociedad Española de Nefrología) Report on Dialysis and Transplantation. Nephrology Dialysis Transplantation, 1999, 14, 2841-2845.	0.7	10
118	Correlation of Serum Magnesium and Serum Lipid Levels in Hemodialysis Patients. Nephron, 1998, 78, 118-119.	1.8	15
119	End-stage renal failure due to diabetic nephropathy in Spain. Nephrology Dialysis Transplantation, 1996, 11, 393-394.	0.7	9
120	Hemodialysis With Cuprophane or Polysulfone: Effects on Uremic Polyneuropathy. American Journal of Kidney Diseases, 1993, 21, 282-287.	1.9	15
121	Membranous Glomerulonephritis after Kidney Transplantation and Urologic Complications. American Journal of Nephrology, 1992, 12, 279-280.	3.1	3
122	Lack of transmission of hepatitis C virus in a haemodialysis unit. Nephrology Dialysis Transplantation, 1992, 7, 981-982.	0.7	10